welcome to oneFAPvoice
- a positively charged Familial Adenomatous Polyposis community.- join today!
- login
Tucson pharmaceutical company sells exclusive option for cancer drug in deal worth up to $190 million
Sucampo unveiled Monday its agreement with Tuscon, Arizona-based Cancer Prevention Pharmaceuticals Inc. for the option to acquire an exclusive license to commercialize for a drug candidate in Phase III clinical trials. The therapy is aimed at treating a genetic condition called Familial Adenomatous Polyposis, or FAP, which can develop into colon cancer if it’s left untreated.

expertly curated content related to this topic
-
darrell henry’s sufferfestThis page is dedicated to Darrell Henry,...
-
Emmanuel TiretEmmanuel Tiret is the Chief of General a...
-
mitchell w. dillonDirector of Genetic Counseling Services ...
-
Melyssa D. Aronson, MS, CGCMelyssa joined Mount Sinai Hospital in 1...
-
Lahey Hospital and Medical CenterLahey Hospital & Medical Center is a...
-
gary mathiasCo-Founder and CEO, Thetis Pharmaceutica...
-
Rachael Brandt, BS, MS, PhDRachael Brandt is a certified genetic co...